Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Investigational New Drugs|January 1, 1985
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European studyH T Mouridsen, M Cornbleet, R Stuart-Harris, et al.
FEMS Immunology and Medical Microbiology|February 15, 2001
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomasJ Theys, W Landuyt, S Nuyts, et al.
The Annals of Thoracic Surgery|January 6, 1999
Isolated lung perfusion with melphalan and tumor necrosis factor for metastatic pulmonary adenocarcinomaJ M Hendriks, P E Van Schil, G De Boeck, et al.
Veterinary Microbiology|August 24, 2010
Comparison of sampling methods used for MRSA-classification of herds with breeding pigsE M Broens, E A M Graat, B Engel, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials GroupU Bruntsch, B Heinrich, S B Kaye, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2001
In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatmentW Landuyt, B Ahmed, S Nuyts, et al.
Progress in Clinical and Biological Research|January 1, 1988
Potential advances in combination chemotherapy for advanced testicular cancerS B Kaye, G Stoter, D Sleijfer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 4, 2006
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumoursM J A de Jonge, H Dumez, J Verweij, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2000
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)N Pavlidis, S Aamdal, A Awada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2006
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumoursH Dumez, A Awada, M Piccart, et al.
Pageof 16